Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing
Promising Antitumor Activity in Multiple Myeloma at ASCO
Tanespimycin TIME Registration Program to Begin Third Quarter 2007 HAYWARD, Calif., June 04, 2007 /PRNewswire-FirstCall/ -- KosanBiosciences Incorporated presented data from a dose-escalatingPhase 1b clinical trial of its lead Hsp90 inhibitor,
tanespimycin(KOS-953) in combination with bortezomib (Velcade(R)), showing ahigh degree of antitumor activity and tolerability in patients withmult...
Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity
of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at ASCO
HAYWARD, Calif., June 04, 2007 /PRNewswire-FirstCall/ -- KosanBiosciences Incorporated presented preliminary data from a Phase 2monotherapy trial showing that
tanespimycin demonstrated antitumoractivity and tolerability in patients with metastatic melanoma,including one patient with a BRAF mutation (V600E) who had failedprior chemotherapy (within 6 weeks of initiation) and while ontanesp...
Kosan Presents Data on Cardiac Safety Profile of Hsp90 Inhibitor
Tanespimycin (KOS-953) at AACR
Tanespimycin Shown to Have No Effect on QTc Interval HAYWARD, Calif., April 16, 2007 /PRNewswire/ -- KosanBiosciences Incorporated today presented safety data frompreclinical and clinical studies of its lead Hsp90 inhibitor,
tanespimycin (KOS-953). Serial electrocardiogram (ECG) monitoringof patients was conducted in four Phase 1 trials of
tanespimycin.Cardiac monitoring analyses were cond...